BackBonus Biogroup Overview

Bonus Biogroup Long Term Debt

Track Bonus Biogroup's long-term debt ($6.3M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$6.33M
↓ 19.69% YoYΔ $-1.55M vs prior year quarter

Peer trimmed avg / median

Loading

Bonus Biogroup Long Term Debt History

Loading

Bonus Biogroup vs. peers: Long Term Debt Comparison

Loading

Bonus Biogroup Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bonus Biogroup (BBIXF) FAQ

As of the most recent data (June 2026), BBIXF shows a long-term debt of $6.3M. That compares with $7.9M in the prior-year period — down 19.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BBIXF's long-term debt is now $6.3M (was $7.9M) — a 19.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Bonus Biogroup is outperforming or lagging.

Tracking BBIXF's long-term debt over time shows whether Bonus Biogroup is scaling, shrinking, or reshaping that part of the business. The current reading is $6.3M That compares with $7.9M in the prior-year period — down 19.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Bonus Biogroup's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $6.3M) with ownership activity and broader fundamentals.

Bonus Biogroup's long-term debt is $6.3M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.

Questions & Answers